Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Salix Pharmaceuticals Gains As FDA Approves Additional Indication for Xiafan

By Pharmaceutical Processing | March 25, 2010

RALEIGH, N.C. (AP) — Shares of Salix Pharmaceuticals rose 9 percent in premarket trading Thursday after regulators approved the sale of its drug to treat neurological problems associated with liver failure.

Xifaxan is currently used to treat diarrhea.

Late Wednesday, the company said that the Food and Drug Administration approved Xifaxan for the treatment of overt hepatic encephalopathy, which can lead to coordination problems, irritability and potentially a coma when the liver is not functioning.

Jefferies & Co. analyst Corey Davis raised his share price target to $42 from $38, and reaffirmed a “Buy” rating.

“Salix proved it has the credibility to execute an on time FDA approval with yesterday’s new indication for hepatic encephalopathy,” he wrote.

The company is also developing Xiaxan as an irritable bowel syndrome drug. Davis said the stock will continue to perform well if the company can deliver positive study data in that indication.

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE